Show simple item record

dc.contributor.authorSampaio, Filipa
dc.contributor.authorFeldman, Inna
dc.contributor.authorLavelle, Tara A.
dc.contributor.authorSkokauskas, Norbert
dc.date.accessioned2021-04-19T09:31:27Z
dc.date.available2021-04-19T09:31:27Z
dc.date.created2021-04-09T13:56:19Z
dc.date.issued2021
dc.identifier.citationEuropean Child and Adolescent Psychiatry. 2021, 1-16.en_US
dc.identifier.issn1018-8827
dc.identifier.urihttps://hdl.handle.net/11250/2738307
dc.description.abstractEconomic evaluations can help decision makers identify what services for children with neurodevelopmental disorders provide best value-for-money. The aim of this paper is to review the best available economic evidence to support decision making for attention defcit-hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) in children and adolescents. We conducted a systematic review of economic evaluations of ADHD and ASD interventions including studies published 2010–2020, identifed through Econlit, Medline, PsychINFO, and ERIC databases. Only full economic evaluations comparing two or more options, considering both costs and consequences were included. The quality of the studies was assessed using the Drummond checklist. We identifed ten studies of moderate-to-good quality on the cost-efectiveness of treatments for ADHD and two studies of good quality of interventions for ASD. The majority of ADHD studies evaluated pharmacotherapy (n=8), and two investigated the economic value of psychosocial/behavioral interventions. Both economic evaluations for ASD investigated early and communication interventions. Included studies support the cost-efectiveness of behavioral parenting interventions for younger children with ADHD. Among pharmacotherapies for ADHD, diferent combinations of stimulant/non-stimulant medications for children were cost-efective at willingness-to-pay thresholds reported in the original papers. Early intervention for children with suspected ASD was cost-efective, but communication-focused therapy for preschool children with ASD was not. Prioritizing more studies in this area would allow decision makers to promote cost-efective and clinically efective interventions for this target group.en_US
dc.language.isoengen_US
dc.publisherSpringeren_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleThe cost-effectiveness of treatments for attention deficit-hyperactivity disorder and autism spectrum disorder in children and adolescents: a systematic reviewen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber1-16en_US
dc.source.journalEuropean Child and Adolescent Psychiatryen_US
dc.identifier.doi10.1007/s00787-021-01748-z
dc.identifier.cristin1903229
dc.description.localcodeOpen Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal